Search

Your search keyword '"Nieweg, Omgo E"' showing total 789 results

Search Constraints

Start Over You searched for: Author "Nieweg, Omgo E" Remove constraint Author: "Nieweg, Omgo E"
789 results on '"Nieweg, Omgo E"'

Search Results

2. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

4. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

6. Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in Australia

8. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

11. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting

12. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

15. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

16. Inguinofemoral, Iliac/Obturator, and Popliteal Lymphadenectomy for Melanoma

17. Lymphoscintigraphy in Patients with Melanoma

22. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

24. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

25. Telehealth follow‐up consultations for melanoma patients during the COVID‐19 pandemic: Patient and clinician satisfaction

26. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease

29. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

30. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

34. ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma

35. Composite haemangioendothelioma with neuroendocrine marker differentiation presenting as a pink–brown nodule.

43. Isolated Limb Perfusion for Melanoma

48. Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma

49. Supplementary Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

50. Data from Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Catalog

Books, media, physical & digital resources